Allogeneic stem cell transplantation for rheumatic autoimmune diseases

Area of Science:

• Immunology
• Hematology
• Transplantation Medicine

Background:

• Haematopoietic stem cell transplantation (HSCT) has transitioned from experimental to a viable treatment for severe autoimmune diseases.
• HSCT possesses a unique capacity to restore immune regulation.
• The procedure involves intensive immunosuppression and stem cell administration.

Purpose of the Study:

• To review the role and risks of HSCT in treating severe autoimmune diseases.
• To discuss the potential of allogeneic HSCT in autoimmune disease management.
• To outline criteria for considering allogeneic HSCT.

Main Methods:

• Review of existing literature, including experimental models, case reports, and registry analyses.
• Focus on autologous and allogeneic HSCT approaches.
• Analysis of risks associated with allogeneic transplantation.

Main Results:

• Autologous HSCT is commonly used for autoimmune diseases.
• Allogeneic HSCT demonstrates curative potential in autoimmune disease models and case studies.
• Significant risks include graft rejection and graft-versus-host disease.

Conclusions:

• Allogeneic HSCT offers curative potential for autoimmune diseases but is associated with substantial risks.
• The risks of allogeneic HSCT must be manageable before wider application.
• Consideration for allogeneic HSCT should be reserved for treatment-refractory cases with suitable donors and potential for significant benefit.